tbuckley/cabot-search huggingface dataset:
IL-9 sensitizes human Th2 cells to pro-inflammatory IL-18 signals in atopic dermatitis
Authors: Stefanie Schärli, Fabian Luther, Jeremy Di Domizio, Christina Hillig, Susanne Radonjic-Hoesli, Kathrin Thormann, Dagmar Simon, Amalie Thorsti Møller Rønnstad, Iben Frier Ruge, Blaine G Fritz, Thomas Bjarnsholt, Angela Vallone, Sanja Kezic, Michael P Menden, Lennart M Roesner, Thomas Werfel, Jacob P Thyssen, Stefanie Eyerich, Michel Gilliet, Nicole L Bertschi, Christoph Schlapbach
Journal: Journal of Allergy and Clinical Immunology (2024)

T helper 2 (Th2) cells crucially contribute to the pathogenesis of atopic dermatitis (AD) by secreting high levels of IL-13 and IL-22. Yet, the upstream regulators that activate Th2 cells in AD skin remain unclear. IL-18 is a putative upstream regulator of Th2 cells as it is implicated in AD pathogenesis and has the capacity to activate T cells.
TMED inhibition suppresses cell surface PD-1 expression and overcomes T cell dysfunction
Authors: David W Vredevoogd, Georgi Apriamashvili, Pierre L Levy, Sanju Sinha, Zowi R Huinen, Nils L Visser, Beaunelle de Bruijn, Julia Boshuizen, Susan E van Hal-van Veen, Maarten A Ligtenberg, Onno B Bleijerveld, Chun-Pu Lin, Judit Díaz-Gómez, Santiago Duro Sánchez, Ettai Markovits, Juan Simon Nieto, Alex van Vliet, Oscar Krijgsman, Gal Markel, Michal J Besser, Maarten Altelaar, Eytan Ruppin, Daniel S Peeper
Journal: Journal for ImmunoTherapy of Cancer (2024)

Blockade of the programmed cell death protein 1 (PD-1) immune checkpoint (ICB) is revolutionizing cancer therapy, but little is known about the mechanisms governing its expression on CD8 T cells. Because PD-1 is induced during activation of T cells, we set out to uncover regulators whose inhibition suppresses PD-1 abundance without adversely impacting on T cell activation.
Melanocortin-4 receptor antagonist TCMCB07 alleviates chemotherapy-induced anorexia and weight loss in rats
Authors: Xinxia Zhu, Russell Potterfield, Kenneth A. Gruber, Emma Zhang, Samuel D. Newton, Mason A. Norgard, Peter R Levasseur, Peng Bai, Xu Chen, Qingyang Gu, Aaron J. Grossberg, Daniel L. Marks
Journal: Journal of Clinical Investigation (2024)

Cancer patients undergoing chemotherapy often experience anorexia and weight loss that substantially deteriorates overall health, reduces treatment tolerance and quality of life, and worsens oncologic outcomes. There are currently few effective therapeutic options to mitigate these side effects. The central melanocortin system, which plays a pivotal role in regulating appetite and energy homeostasis, presents a logical target for treating anorexia and weight loss. In this preclinical study, we evaluated the efficacy of TCMCB07, a synthetic antagonist of the melanocortin-4 receptor, in mitigating anorexia and weight loss in several rat models of chemotherapy: cisplatin, 5-fluorouracil, cyclophosphamide, vincristine, doxorubicin, and a combination of irinotecan and 5-fluorouracil. Our results indicate that peripheral administration of TCMCB07 improved appetite, stabilized body weight, preserved fat and heart mass, and slightly protected lean mass after multiple cycles of chemotherapy. Furthermore, combining TCMCB07 with a growth differentiation factor 15 antibody enhanced treatment effectiveness. Similar effects from TCMCB07 treatment were observed in a rat tumor model following combination chemotherapy. No notable adverse effects nor increased chemotherapy-related toxicities were observed with TCMCB07 treatment. These findings suggest that peripheral administration of TCMCB07 holds promise as a therapeutic approach for alleviating chemotherapy-induced anorexia and weight loss, potentially benefiting numerous patients undergoing chemotherapy.
Progranulin-dependent repair function of Regulatory T cells drive bone fracture healing
Authors: Ruiying Chen, Xiaomeng Zhang, Bin Li, Maurizio S. Tonetti, Yijie Yang, Yuan Li, Beilei Liu, Shujiao Qian, Yingxin Gu, Qingwen Wang, Kairui Mao, Hao Cheng, Hongchang Lai, Junyu Shi
Journal: Journal of Clinical Investigation (2024)

Local immunoinflammatory events instruct skeletal stem cells (SSCs) to repair/regenerate bone after injury, but mechanisms are incompletely understood. We hypothesized that specialized Regulatory T (Treg) cells are necessary for bone repair and interact directly with SSCs through organ-specific messages. Both in human patients with bone fracture and mouse model of bone injury, we identified a bone injury-responding Treg subpopulation with bone-repair capacity marked by CCR8. Local production of CCL1 induced a massive migration of CCR8+ Treg cells from periphery to the injury site. Depending on secretion of progranulin (PGRN), a protein encoded by the granulin (Grn) gene, CCR8+ Treg cells supported the accumulation and osteogenic differentiation of SSCs, and thereby bone repair. Mechanistically, we revealed that CCL1 enhanced expression level of basic leucine zipper ATF-like transcription factor (BATF) in CCR8+ Treg cells, which bound to Grn promoter and increased Grn translational output and then PGRN secretion. Together, our work provides a new perspective in osteoimmunology and highlights possible ways of manipulating Treg cell signaling to enhance bone repair and regeneration.
The Phase 3 KEYLYNK-006 Study of Pembrolizumab plus Olaparib versus Pembrolizumab plus Pemetrexed as Maintenance Therapy for Metastatic Nonsquamous Non–Small-Cell Lung Cancer
Authors: Jhanelle E Gray, Michael Schenker, Mehmet Ali Nahit Şendur, Viktoriya Leonova, Dariusz Kowalski, Terufumi Kato, Rashida Orlova, James Chih-Hsin Yang, Adrian Langleben, Arnold Pilz, Andrei Ungureanu, Milena Perez Mak, None Flavia De Angelis, Himani Aggarwal, Zachary Zimmer, Bin Zhao, Mark Shamoun, Tae Min Kim
Journal: Journal of Thoracic Oncology (2024)
Body mass index and type 2 diabetes mellitus as metabolic determinants of immune checkpoint inhibitors response in melanoma
Authors: Yu Jen Alexander Jan, Cho-Han Chiang, Soravis Osataphan, Aleigha R Lawless, Kerry L Reynolds, Ryan J Sullivan
Journal: Journal for ImmunoTherapy of Cancer (2024)

Immune checkpoint inhibitors (ICIs) have improved survival outcomes in melanoma. Studies exploring the correlations between body mass index (BMI), type 2 diabetes (T2DM) and the outcomes of ICI treatment have yielded inconsistent results. In this study, we aim to investigate the effects of BMI and T2DM on survival outcomes of patients with melanoma receiving ICIs.
Error in Author Name
Journal: JAMA Network Open (2024)

Dana P. Edelson, MD, MS; Matthew M. Churpek, MD, MPH, PhD; Kyle A. Carey, MPH; Zhenqiu Lin, PhD; Chenxi Huang, PhD; Jonathan M. Siner, MD; Jennifer Johnson, MSN, APRN; Harlan M. Krumholz, MD, SM; Deborah J. Rhodes, MD
Neurodevelopment in the First 2 Years of Life Following Prenatal Exposure to Maternal SARS-CoV-2 Infection
Authors: Daphne M. Vrantsidis, Marcel van de Wouw, Emily R. M. Hall, Verena Kuret, Charlie Rioux, Melanie L. Conrad, Christine Mesa, Angela Harris, Catherine Lebel, Lianne Tomfohr-Madsen, Gerald F. Giesbrecht
Journal: JAMA Network Open (2024)

The effects of prenatal exposure to SARS-CoV-2 infection on child development throughout the first 2 years of life are unknown.
Age and Late Recurrence in Young Patients With ER–Positive, <i>ERBB2</i>-Negative Breast Cancer
Authors: Dong Seung Shin, Janghee Lee, Eunhye Kang, Dasom Noh, Jong-Ho Cheun, Jun-Hee Lee, Yeongyeong Son, Soong June Bae, Seok Won Kim, Jeong Eon Lee, Jonghan Yu, Byung-Joo Chae, Sunyoung Kwon, Han-Byoel Lee, Sung Gwe Ahn, Jai Min Ryu
Journal: JAMA Network Open (2024)

Young patients with breast cancer with estrogen receptor (ER)-positive, ERBB2-negative tumors have a poor prognosis. Understanding factors influencing late recurrence is crucial for improving management and outcomes.
Primary Care Practice Telehealth Use and Low-Value Care Services
Authors: Terrence Liu, Ziwei Zhu, Michael P. Thompson, Jeffrey S. McCullough, Hechuan Hou, Chiang-Hua Chang, A. Mark Fendrick, Chad Ellimoottil
Journal: JAMA Network Open (2024)

The rapid expansion of telehealth transformed how primary care practices deliver care; however, uncertainties about the quality of telehealth-delivered care compared with in-person care remain. While there are concerns that increased telehealth may introduce wasteful care, how telehealth affects the delivery of low-value care is unknown.
PD-L1 Expression for Tailoring Treatment in Advanced Melanoma—It Is Never That Easy—Reply
Authors: Marco Donia, Inge Marie Svane
Journal: JAMA Oncology (2024)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast JAMA+ AI Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
Childhood Community Disadvantage and MRI-Derived Structural Brain Integrity After Age 65 Years
Authors: Rachel L. Peterson, Erika Meza, Kristen M. George, Pauline Maillard, Charles DeCarli, Paola Gilsanz, Yenee Soh, Yi Lor, Amy J. Kind, Lisa L. Barnes, Rachel A. Whitmer
Journal: JAMA Network Open (2024)

Prior studies associate late-life community disadvantage with worse brain health. It is relatively unknown if childhood community disadvantage associates with late-life brain health.
Costs and Access Barriers to Ondansetron in the US
Authors: Changchuan Jiang, K. Robin Yabroff, Ryan D. Nipp, Xuesong Han, Xin Hu, Joshua M. Liao, Ya-Chen Tina Shih
Journal: JAMA Network Open (2024)

This cross-sectional study compares the use of management tools and plan-level total costs for oral ondansetron between Part D independent prescription drug plans and Medicare Advantage prescription drug plans.
Natural Language Processing of Clinical Documentation to Assess Functional Status in Patients With Heart Failure
Authors: Philip Adejumo, Phyllis M. Thangaraj, Lovedeep Singh Dhingra, Arya Aminorroaya, Xinyu Zhou, Cynthia Brandt, Hua Xu, Harlan M. Krumholz, Rohan Khera
Journal: JAMA Network Open (2024)

Serial functional status assessments are critical to heart failure (HF) management but are often described narratively in documentation, limiting their use in quality improvement or patient selection for clinical trials.
Diffuse lung diseases ascribed to drugs: a nationwide observational study over 37 years using the French pharmacovigilance database
Authors: Sophie Yavordios, Guillaume Beltramo, Romane Freppel, Frédérique Beau Salinas, Christine Le Beller, Kevin Bihan, Pierre Mouillot, Marjolaine Georges, Aurélie Grandvuillemin, Philippe Bonniaud
Journal: European Respiratory Journal (2024)

Drug-induced interstitial lung disease (DI-ILD) is a heterogeneous subgroup of interstitial lung diseases (ILD). The number of molecules involved is increasing with time. Due to their low incidence, DI-ILDs may be detected only after a drug has been marketed, notably through Adverse Drug Reaction (ADR) reports to pharmacovigilance centres. The aim of our study was to describe drug-induced diffuse lung disease cases notified to and recorded by the French Pharmacovigilance Database (FPVD), reported clinical pictures and the potentially causal drugs.
Generalizability of pharmaceutical randomized controlled trial eligibility criteria for progressive pulmonary fibrosis
Authors: Yet H. Khor, Kerri A. Johannson, Veronica Marcoux, Jolene H. Fisher, Deborah Assayag, Helene Manganas, Nasreen Khalil, Daniel-Costin Marinescu, Nestor L. Muller, Martin Kolb, Christopher J. Ryerson
Journal: European Respiratory Journal (2024)

Progressive pulmonary fibrosis (PFF) is of substantial interest for novel pharmacotherapy discovery, but little is known about clinical trial eligibility criteria. We evaluated eligibility criteria of PPF randomized controlled trials (RCTs), their representativeness in registry patients, and forced vital capacity (FVC) changes and mortality according to trial eligibility.
Respiratory support and bronchopulmonary dysplasia in infants born at 22-26 weeks gestation in Sweden, 2004-2007 and 2014-2016
Authors: Linn Löfberg, Thomas Abrahamsson, Lars J Björklund, Lena Hellström Westas, Aijaz Farooqi, Magnus Domellöf, Ulrika Ådén U, Christian Gadsbøll, Karin Källén, David Ley, Erik Normann, Karin Sävman, Anders Elfvin, Stellan Håkansson, Mikael Norman, Richard Sindelar, Fredrik Serenius, Petra Um-Bergström
Journal: European Respiratory Journal (2024)

To evaluate if increased survival and new ventilation strategies were accompanied by a changed incidence of bronchopulmonary dysplasia (BPD) in Sweden over a decade.
Pirfenidone and risk of lung cancer development in IPF: a nationwide population-based study
Authors: Hee-Young Yoon, Hoseob Kim, Yoonjong Bae, Jin Woo Song
Journal: European Respiratory Journal (2024)

Idiopathic pulmonary fibrosis (IPF) carries a high risk of lung cancer, but the effect of pirfenidone on lung cancer development remains uncertain. We investigated the association between pirfenidone use and lung cancer development in patients with IPF.
Pulmonary gas exchange in relation to exercise pulmonary hypertension in patients with heart failure with preserved ejection fraction
Authors: Bryce N. Balmain, Andrew R. Tomlinson, Josh T. Goh, James P. MacNamara, Denis J. Wakeham, Tiffany L. Brazile, Michael G. Leahy, Kevin C. Lutz, Linda S. Hynan, Benjamin D. Levine, Satyam Sarma, Tony G. Babb
Journal: European Respiratory Journal (2024)

Exercise pulmonary hypertension (ePH), defined as a mean pulmonary artery pressure (mPAP)/cardiac output (Qc) slope >3 WU during exercise, is common in patients with heart failure with preserved ejection fraction (HFpEF). However, the pulmonary gas exchange-related effects of an exaggerated ePH (EePH) response are not well-defined, especially in relation to dyspnea on exertion (DOE) and exercise intolerance.
Targeting the immune privilege of tumor-initiating cells to enhance cancer immunotherapy
Authors: Chen Yang, Haigang Geng, Xupeng Yang, Shuyi Ji, Zhicheng Liu, Hao Feng, Qian Li, Tangansu Zhang, Sisi Zhang, Xuhui Ma, Chuchen Zhu, Nuo Xu, Yuhan Xia, Yan Li, Hongye Wang, Chune Yu, Shangce Du, Beiping Miao, Lei Xu, Hui Wang, Ying Cao, Botai Li, Lili Zhu, Xiangyu Tang, Haoyu Zhang, Chunchao Zhu, Zhao Huang, Chao Leng, Haiyan Hu, Xiaoping Chen, Shengxian Yuan, Guangzhi Jin, René Bernards, Chong Sun, Quan Zheng, Wenxin Qin, Qiang Gao, Cun Wang
Journal: Cancer Cell (2024)
Cytometry masked autoencoder: An accurate and interpretable automated immunophenotyper
Authors: Jaesik Kim, Matei Ionita, Matthew Lee, Michelle L McKeague, Ajinkya Pattekar, Mark M Painter, Joost Wagenaar, Van Truong, Dylan T Norton, Divij Mathew, Yonghyun Nam, Sokratis A Apostolidis, Cynthia Clendenin, Patryk Orzechowski, Sang-Hyuk Jung, Jakob Woerner, Caroline A G Ittner, Alexandra P Turner, Mika Esperanza, Thomas G Dunn, Nilam S Mangalmurti, John P Reilly, Nuala J Meyer, Carolyn S Calfee, Kathleen D Liu, Michael A Matthy, Lamorna Brown Swigart, Ellen L Burnham, Jeffrey McKeehan, Sheetal Gandotra, Derek W Russel, Kevin W Gibbs, Karl W Thomas, Harsh Barot, Allison R Greenplate, E John Wherry, Dokyoon Kim
Journal: Cell Reports Medicine (2024)

Single-cell cytometry data are crucial for understanding the role of the immune system in diseases and responses to treatment. However, traditional methods for annotating cytometry data face challenges in scalability, robustness, and accuracy. We propose a cytometry masked autoencoder (cyMAE), which automates immunophenotyping tasks including cell type annotation. The model upholds user-defined cell type definitions, facilitating interpretability and cross-study comparisons. The training of cyMAE has a self-supervised phase, which leverages large amounts of unlabeled data, followed by fine-tuning on specialized tasks using smaller amounts of annotated data. The cost of training a new model is amortized over repeated inferences on new datasets using the same panel. Through validation across multiple studies using the same panel, we demonstrate that cyMAE delivers accurate and interpretable cellular immunophenotyping and improves the prediction of subject-level metadata. This proof of concept marks a significant step forward for large-scale immunology studies.
A prefrontal thalamocortical readout for conflict-related executive dysfunction in schizophrenia
Authors: Anna S. Huang, Ralf D. Wimmer, Norman H. Lam, Bin A. Wang, Sahil Suresh, Maxwell J. Roeske, Burkhard Pleger, Michael M. Halassa, Neil D. Woodward
Journal: Cell Reports Medicine (2024)

Highlights•Developed a task to interrogate allocating attention with conflicting inputs•People with schizophrenia are more susceptible to conflicting inputs•Right MD-dlPFC functional connectivity as readout for conflict-related executive deficitSummaryExecutive dysfunction is a prominent feature of schizophrenia and may drive core symptoms. Dorsolateral prefrontal cortex (dlPFC) deficits have been linked to schizophrenia executive dysfunction, but mechanistic details critical for treatment development remain unclear. Here, capitalizing on recent animal circuit studies, we develop a task predicted to engage human dlPFC and its interactions with the mediodorsal thalamus (MD). We find that individuals with schizophrenia exhibit selective performance deficits when attention is guided by conflicting cues. Task performance correlates with lateralized MD-dlPFC functional connectivity, identifying a neural readout that predicts susceptibility to conflict during working memory in a larger independent schizophrenia cohort. In healthy subjects performing a probabilistic reversal task, this MD-dlPFC network predicts switching behavior. Overall, our three independent experiments introduce putative biomarkers for executive function in schizophrenia and highlight animal circuit studies as inspiration for the development of clinically relevant readouts.Graphical abstract
Pulmonary hypertension in patients carrying FLNA loss-of-function variants
Authors: Laura Stourm, Julien Grynblat, Laurent Savale, Thomas Lacoste-Palasset, Xavier Jaïs, Florence Coulet, Marilyne Levy, Olivier Meyrignac, Maria-Rosa Ghigna, Vincent Cottin, Olivier Sitbon, Damien Bonnet, Francois Goupil, Marc Humbert, Frederic Gagnadoux, David Montani
Journal: European Respiratory Journal (2024)

Pulmonary hypertension (PH) is an unusual complication of X-linked disease caused by loss-of-function (LOF) variants in the
NMDA receptors regulate the firing rate set point of hippocampal circuits without altering single-cell dynamics
Authors: Antonella Ruggiero, Leore R. Heim, Lee Susman, Dema Hreaky, Ilana Shapira, Maxim Katsenelson, Kobi Rosenblum, Inna Slutsky
Journal: Neuron (2024)

Highlights•Hippocampal firing is actively regulated around a network-level set point•Blocking NMDARs reduces this set point without impairing compensatory responses•Intrinsic plasticity of PV neurons mediates this novel NMDAR function via eEF2K•NMDARs regulate E/I ratio and network firing without affecting single-neuron driftSummaryUnderstanding how neuronal circuits stabilize their activity is a fundamental yet poorly understood aspect of neuroscience. Here, we show that hippocampal network properties, such as firing rate distribution and dimensionality, are actively regulated, despite perturbations and single-cell drift. Continuous inhibition of N-methyl-D-aspartate receptors (NMDARs) ex vivo lowers the excitation/inhibition ratio and network firing rates while preserving resilience to perturbations. This establishes a new network firing rate set point via NMDAR-eEF2K signaling pathway. NMDARs' capacity to modulate and stabilize network firing is mediated by excitatory synapses and the intrinsic excitability of parvalbumin-positive neurons, respectively. In behaving mice, continuous NMDAR blockade in CA1 reduces network firing without altering single-neuron drift or triggering a compensatory response. These findings expand NMDAR function beyond their canonical role in synaptic plasticity and raise the possibility that some NMDAR-dependent behavioral effects are mediated by their unique regulation of population activity set points.Graphical abstract
PD-L1 Expression for Tailoring Treatment in Advanced Melanoma—It Is Never That Easy
Authors: Latif Karahan, Mutlu Hayran, Omer Dizdar
Journal: JAMA Oncology (2024)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast JAMA+ AI Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
Itaconate transporter SLC13A3 impairs tumor immunity via endowing ferroptosis resistance
Authors: Heng Lin, Kole Tison, Yuheng Du, Paul Kirchhoff, Chan Kim, Weichao Wang, Hannah Yang, Michael Pitter, Jiali Yu, Peng Liao, Jiajia Zhou, Linda Vatan, Sara Grove, Shuang Wei, Thomas Vigil, Yatrik M Shah, Richard Mortensen, Ilona Kryczek, Lana Garmire, Jwala P Sivaccumar, Ashwin Kumar Ramesh, Ningyan Zhang, Zhiqiang An, Shaomeng Wang, Weiping Zou
Journal: Cancer Cell (2024)

Immune checkpoint blockade (ICB) triggers tumor ferroptosis. However, most patients are unresponsive to ICB. Tumors might evade ferroptosis in the tumor microenvironment (TME). Here, we discover SLC13A3 is an itaconate transporter in tumor cells and endows tumor ferroptosis resistance, diminishing tumor immunity and ICB efficacy. Mechanistically, tumor cells uptake itaconate via SLC13A3 from tumor-associated macrophages (TAMs), thereby activating the NRF2-SLC7A11 pathway and escaping from immune-mediated ferroptosis. Structural modeling and molecular docking analysis identify a functional inhibitor for SLC13A3 (SLC13A3i). Deletion of ACOD1 (an essential enzyme for itaconate synthesis) in macrophages, genetic ablation of SLC13A3 in tumors, or treatment with SLC13A3i sensitize tumors to ferroptosis, curb tumor progression, and bolster ICB effectiveness. Thus, we identify the interplay between tumors and TAMs via the SLC13A3-itaconate-NRF2-SLC7A11 axis as a previously unknown immune ferroptosis resistant mechanism in the TME and SLC13A3 as a promising immunometabolic target for treating SLC13A3